| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 International Agency for Research on Cancer, Lyon, France; 2 Cancer Registry, Canton of Zurich, Zurich, Switzerland; 3 Department of Neurosurgery, College of Medicine, Little Rock, Arkansas; and 4 Departments of Neurosurgery, Radiology, and Pathology, University Hospital Zurich, Zurich, Switzerland
We conducted a population-based study on glioblastomas in the Canton of Zurich, Switzerland (population, 1.16 million) to determine the frequency of major genetic alterations and their effect on patient survival. Between 1980 and 1994, 715 glioblastomas were diagnosed. The incidence rate per 100,000 population/year, adjusted to the World Standard Population, was 3.32 in males and 2.24 in females. Observed survival rates were 42.4% at 6 months, 17.7% at 1 year, and 3.3% at 2 years. For all of the age groups, younger patients survived significantly longer, ranging from a median of 8.8 months (<50 years) to 1.6 months (>80 years). Loss of heterozygosity (LOH) 10q was the most frequent genetic alteration (69%), followed by EGFR amplification (34%), TP53 mutations (31%), p16INK4a deletion (31%), and PTEN mutations (24%). LOH 10q occurred in association with any of the other genetic alterations and was predictive of shorter survival. Primary (de novo) glioblastomas prevailed (95%), whereas secondary glioblastomas that progressed from low-grade or anaplastic gliomas were rare (5%). Secondary glioblastomas were characterized by frequent LOH 10q (63%) and TP53 mutations (65%). Of the TP53 mutations in secondary glioblastomas, 57% were in hotspot codons 248 and 273, whereas in primary glioblastomas, mutations were more equally distributed. G:C
A:T mutations at CpG sites were more frequent in secondary than primary glioblastomas (56% versus 30%; P = 0.0208). This suggests that the acquisition of TP53 mutations in these glioblastoma subtypes occurs through different mechanisms.
This article has been cited by other articles:
|
|
 |
|
  J. Sigmond, R. J. Honeywell, T. J. Postma, C. M. F. Dirven, S. M. de Lange, K. van der Born, A. C. Laan, J. C. A. Baayen, C. J. Van Groeningen, A. M. Bergman, et al. Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer Ann. Onc., August 12, 2008; (2008) mdn543v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. P. Mason and J. G. Cairncross Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas Neurology, July 29, 2008; 71(5): 365 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Reddy, R. Britto, K. Vinnakota, H. Aparna, H. K. Sreepathi, B. Thota, A. Kumari, B.M. Shilpa, M. Vrinda, S. Umesh, et al. Novel Glioblastoma Markers with Diagnostic and Prognostic Value Identified through Transcriptome Analysis Clin. Cancer Res., May 15, 2008; 14(10): 2978 - 2987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Kwon, D. Zhao, J. Chen, S. Alcantara, Y. Li, D. K. Burns, R. P. Mason, E. Y.-H. P. Lee, H. Wu, and L. F. Parada Pten Haploinsufficiency Accelerates Formation of High-Grade Astrocytomas Cancer Res., May 1, 2008; 68(9): 3286 - 3294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, F. Guessous, S. Kwon, M. Kumar, O. Ibidapo, L. Fuller, E. Johnson, B. Lal, I. Hussaini, Y. Bao, et al. PTEN Has Tumor-Promoting Properties in the Setting of Gain-of-Function p53 Mutations Cancer Res., March 15, 2008; 68(6): 1723 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Huszthy, D. Goplen, F. Thorsen, H. Immervoll, J. Wang, A. Gutermann, H. Miletic, and R. Bjerkvig Oncolytic Herpes Simplex Virus Type-1 Therapy in a Highly Infiltrative Animal Model of Human Glioblastoma Clin. Cancer Res., March 1, 2008; 14(5): 1571 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Filippini, C. Falcone, A. Boiardi, G. Broggi, M. G. Bruzzone, D. Caldiroli, R. Farina, M. Farinotti, L. Fariselli, G. Finocchiaro, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma Neuro-oncol, February 1, 2008; 10(1): 79 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Aoki, T. Yokoyama, K. Fujiwara, A. M. Tari, R. Sawaya, D. Suki, K. R. Hess, K. D. Aldape, S. Kondo, R. Kumar, et al. Phosphorylated Pak1 Level in the Cytoplasm Correlates with Shorter Survival Time in Patients with Glioblastoma Clin. Cancer Res., November 15, 2007; 13(22): 6603 - 6609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes & Dev., November 1, 2007; 21(21): 2683 - 2710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Krex, B. Klink, C. Hartmann, A. von Deimling, T. Pietsch, M. Simon, M. Sabel, J. P. Steinbach, O. Heese, G. Reifenberger, et al. Long-term survival with glioblastoma multiforme Brain, October 1, 2007; 130(10): 2596 - 2606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Axelsen, J. Lotem, L. Sachs, and E. Domany Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles PNAS, August 7, 2007; 104(32): 13122 - 13127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Aoki, Y. Takada, S. Kondo, R. Sawaya, B. B. Aggarwal, and Y. Kondo Evidence That Curcumin Suppresses the Growth of Malignant Gliomas in Vitro and in Vivo through Induction of Autophagy: Role of Akt and Extracellular Signal-Regulated Kinase Signaling Pathways Mol. Pharmacol., July 1, 2007; 72(1): 29 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Sandsmark, H. Zhang, B. Hegedus, C. L. Pelletier, J. D. Weber, and D. H. Gutmann Nucleophosmin Mediates Mammalian Target of Rapamycin-Dependent Actin Cytoskeleton Dynamics and Proliferation in Neurofibromin-Deficient Astrocytes Cancer Res., May 15, 2007; 67(10): 4790 - 4799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ohgaki and P. Kleihues Genetic Pathways to Primary and Secondary Glioblastoma Am. J. Pathol., May 1, 2007; 170(5): 1445 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Eoli, F. Menghi, M. G. Bruzzone, T. De Simone, L. Valletta, B. Pollo, L. Bissola, A. Silvani, D. Bianchessi, L. D'Incerti, et al. Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival Clin. Cancer Res., May 1, 2007; 13(9): 2606 - 2613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nakamura, K. Shimada, E. Ishida, T. Higuchi, H. Nakase, T. Sakaki, and N. Konishi Molecular pathogenesis of pediatric astrocytic tumors Neuro-oncol, April 1, 2007; 9(2): 113 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Broniscer, S. J. Baker, A. N. West, M. M. Fraser, E. Proko, M. Kocak, J. Dalton, G. P. Zambetti, D. W. Ellison, L. E. Kun, et al. Clinical and Molecular Characteristics of Malignant Transformation of Low-Grade Glioma in Children J. Clin. Oncol., February 20, 2007; 25(6): 682 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Semmler, M. Simon, S. Moskau, and M. Linnebank The Methionine Synthase Polymorphism c.2756A>G Alters Susceptibility to Glioblastoma Multiforme. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2314 - 2316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kotliarov, M. E. Steed, N. Christopher, J. Walling, Q. Su, A. Center, J. Heiss, M. Rosenblum, T. Mikkelsen, J. C. Zenklusen, et al. High-resolution Global Genomic Survey of 178 Gliomas Reveals Novel Regions of Copy Number Alteration and Allelic Imbalances Cancer Res., October 1, 2006; 66(19): 9428 - 9436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Muraoka-Cook, L. S. Caskey, M. A. Sandahl, D. M. Hunter, C. Husted, K. E. Strunk, C. I. Sartor, W. A. Rearick Jr., W. McCall, M. K. Sgagias, et al. Heregulin-Dependent Delay in Mitotic Progression Requires HER4 and BRCA1. Mol. Cell. Biol., September 1, 2006; 26(17): 6412 - 6424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-L. Tso, P. Shintaku, J. Chen, Q. Liu, J. Liu, Z. Chen, K. Yoshimoto, P. S. Mischel, T. F. Cloughesy, L. M. Liau, et al. Primary Glioblastomas Express Mesenchymal Stem-Like Properties Mol. Cancer Res., September 1, 2006; 4(9): 607 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Wei, L. Clarke, D. K. Scheidenhelm, B. Qian, A. Tong, N. Sabha, Z. Karim, N. A. Bock, R. Reti, R. Swoboda, et al. High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res., August 1, 2006; 66(15): 7429 - 7437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. McCubrey, M. M. LaHair, and R. A. Franklin OSU-03012 in the Treatment of Glioblastoma Mol. Pharmacol., August 1, 2006; 70(2): 437 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wrensch, J. K. Wiencke, J. Wiemels, R. Miike, J. Patoka, M. Moghadassi, A. McMillan, K. T. Kelsey, K. Aldape, K. R. Lamborn, et al. Serum IgE, Tumor Epidermal Growth Factor Receptor Expression, and Inherited Polymorphisms Associated with Glioma Survival. Cancer Res., April 15, 2006; 66(8): 4531 - 4541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner Recent Advances in the Treatment of Malignant Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ghosh and G. J. Duigou Decreased Replication Ability of E1-Deleted Adenoviruses Correlates with Increased Brain Tumor Malignancy Cancer Res., October 1, 2005; 65(19): 8936 - 8943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Wiencke, K. Aldape, A. McMillan, J. Wiemels, M. Moghadassi, R. Miike, K. T. Kelsey, J. Patoka, J. Long, and M. Wrensch Molecular Features of Adult Glioma Associated with Patient Race/Ethnicity, Age, and a Polymorphism in O6-Methylguanine-DNA-Methyltransferase Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1774 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-Y. Chou, C.-H. Chiu, L.-H. Li, C.-Y. Hsiao, C.-Y. Tzen, K.-T. Chang, Y.-M. Chen, R.-P. Perng, S.-F. Tsai, and C.-M. Tsai Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3750 - 3757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rahnenfuhrer, N. Beerenwinkel, W. A. Schulz, C. Hartmann, A. von Deimling, B. Wullich, and T. Lengauer Estimating cancer survival and clinical outcome based on genetic tumor progression scores Bioinformatics, May 15, 2005; 21(10): 2438 - 2446. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
